Low nutrient intake and early growth for later insulin resistance in adolescents born preterm

Atul Singhal1, Mary Fewtrell, Tim J Cole

  • 1The MRC Childhood Nutrition Research Centre, Institute of Child Health, London, UK. a.singhal@ich.ucl.ac.uk <a.singhal@ich.ucl.ac.uk>

PubMed

Insights

Relative undernutrition in preterm infants may benefit later insulin resistance. Lower nutrient intake in early life was associated with lower insulin resistance markers in adolescents born preterm.

Area of Science:

  • Neonatal nutrition and metabolic health
  • Endocrinology and diabetes research

Background:

  • Neonatal growth acceleration is linked to later insulin resistance and diabetes in animals.
  • This study investigates the long-term effects of neonatal nutrition on insulin resistance in preterm infants.

Purpose of the Study:

  • To test the hypothesis that early undernutrition benefits insulin resistance in preterm infants.
  • To compare insulin resistance markers in preterm adolescents based on neonatal diet interventions.

Main Methods:

  • Fasting 32-33 split proinsulin concentrations were measured in adolescents (13-16 years) born preterm.
  • Participants were randomized to nutrient-enriched or lower-nutrient neonatal diets (n=216) or a term-born reference group (n=61).

Main Results:

  • Higher proinsulin concentrations were observed in the nutrient-enriched preterm group compared to the lower-nutrient preterm group (p=0.01).
  • Term-born infants had similar proinsulin levels to the nutrient-enriched preterm group.
  • Early weight gain in preterm infants was associated with increased proinsulin levels.

Conclusions:

  • Relative undernutrition in early life may offer protective effects against insulin resistance in preterm infants.
  • Neonatal nutrition strategies can influence later metabolic health outcomes.
Abstract

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...